Collectively, these results suggest that CXCL13 produced by Tph cells plays a significant role in the development of iMCD-like systemic inflammation in iMCD-NOS NSG mice, providing a rationale for CXCL13-targeting therapeutic applications in the treatment of iMCD-NOS. This evidence concerns the gene TPH1 and inflammation.